Published in Br J Cancer on May 19, 2003
Issues related to targeted delivery of proteins and peptides. AAPS J (2006) 0.98
Enzyme/Prodrug Systems for Cancer Gene Therapy. Curr Pharmacol Rep (2016) 0.75
Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene (1989) 60.30
Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol (1985) 25.52
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20
The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell (1994) 4.35
United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer (1998) 4.33
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Halting angiogenesis suppresses carcinoma cell invasion. Nat Med (1997) 2.61
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem (1997) 2.12
Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun (1989) 1.91
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A (1991) 1.89
Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci U S A (1987) 1.48
Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci (1999) 1.44
Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem (1985) 1.38
Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1992) 1.14
Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res (1988) 1.10
Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol (1991) 1.04
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res (2000) 0.98
Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res (1996) 0.97
Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer (1990) 0.97
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem (1995) 0.96
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res (1999) 0.94
A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotechnol (1997) 0.91
Self-immolative anthracycline prodrugs for suicide gene therapy. J Med Chem (1999) 0.90
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol (1997) 0.89
Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis Markers (1992) 0.86
Antibody-directed enzyme/prodrug therapy (ADEPT). Biochem Soc Trans (1990) 0.85
Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther (2000) 0.84
Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res (1995) 0.83
In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther (2000) 0.81
Evaluation of equilibrium constants for antigen-antibody interactions by solid-phase immunoassay: the binding of paraquat to its elicited mouse monoclonal antibody. Mol Immunol (1987) 0.81
Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg (1993) 0.80
Heparin-binding transforming growth factor alpha-Pseudomonas exotoxin A. A heparan sulfate-modulated recombinant toxin cytotoxic to cancer cells and proliferating smooth muscle cells. J Biol Chem (1993) 0.80
Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor. J Immunol (1992) 0.80
Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol (1999) 0.79
Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother Pharmacol (1997) 0.79
Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. Cancer Res (1991) 0.78
Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin. Bioconjug Chem (1994) 0.78
Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother Pharmacol (1988) 0.76
HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J Biol Chem (1995) 0.76
Are the problems of primary care in inner cities fact or fiction? Br Med J (Clin Res Ed) (1983) 7.90
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet (1998) 4.01
The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene (2010) 4.00
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
Functional analysis of a growth factor-responsive transcription factor complex. Cell (1993) 3.66
Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem (1994) 3.50
Does the underprivileged area index work? Br Med J (Clin Res Ed) (1985) 3.35
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer (2006) 3.23
Mouse thymus-independent and thymus-derived lymphoid cells. I. Immunofluorescent and functional studies. J Exp Med (1972) 2.96
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol (1990) 2.87
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 2.79
An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol (1985) 2.68
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Professional attitudes to patient participation groups: an exploratory study. J R Coll Gen Pract (1980) 2.56
Can some in-hospital cardio-respiratory arrests be prevented? A prospective survey. Resuscitation (1998) 2.44
Differentiation of normal and abnormal airway protection during swallowing using the penetration-aspiration scale. Dysphagia (1999) 2.44
Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci (2001) 2.43
MEK kinase activity is not necessary for Raf-1 function. EMBO J (2001) 2.36
Prophylactic use of oxytocin in the third stage of labour. Cochrane Database Syst Rev (2001) 2.30
Spatial flexibility in ternary complexes between SRF and its accessory proteins. EMBO J (1992) 2.28
Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry (2010) 2.21
Rapid immune response to influenza vaccination. Lancet (1993) 2.09
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
Strand displacement amplification and homogeneous real-time detection incorporated in a second-generation DNA probe system, BDProbeTecET. Clin Chem (1999) 2.01
Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular cancer. BJU Int (2001) 1.94
Retracted A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer (1989) 1.93
Etiology of acute conjunctivitis in children. J Pediatr (1981) 1.92
A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci (2006) 1.92
Age effects on lingual pressure generation as a risk factor for dysphagia. J Gerontol A Biol Sci Med Sci (1995) 1.82
Iron-induced mucosal pathology of the upper gastrointestinal tract: a common finding in patients on oral iron therapy. Histopathology (2008) 1.78
Autophagic vacuoles in experimental atrophy. Exp Mol Pathol (1971) 1.75
Learning rate for laparoscopic surgical skills on MIST VR, a virtual reality simulator: quality of human-computer interface. Ann R Coll Surg Engl (1999) 1.73
The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol (1995) 1.71
Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Methods (1990) 1.67
A clinical assessment of nine pregnancies obtained by in vitro fertilization and embryo transfer. Fertil Steril (1981) 1.67
Increased nuclease activity in cells treated with pppA2'p5'A2'p5' A. Proc Natl Acad Sci U S A (1979) 1.66
Homo- and heterocellular junctions in cell cultures: an electrophysiological and morphological study. Prog Brain Res (1969) 1.65
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des (2000) 1.63
A rat model of bone cancer pain. Pain (2002) 1.61
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst (2001) 1.59
Evidence based assessment. Br Dent J (1996) 1.57
Bone marrow transplantation from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Xenotransplantation (2004) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
A case control study of multiple myeloma at four nuclear facilities. Ann Epidemiol (2000) 1.55
Tricuspid replacement for acquired valve disease. Surg Gynecol Obstet (1966) 1.54
Clock mutations alter developmental timing in Drosophila. Heredity (Edinb) (1990) 1.53
A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer (1988) 1.52
Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav (2006) 1.51
Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc Natl Acad Sci U S A (2000) 1.49
Monitoring Section 63 activities. J R Coll Gen Pract (1977) 1.49
Lymphocyte subpopulations in the blood of newborn infants. Clin Exp Immunol (1974) 1.48
The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol (1992) 1.47
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Mouse thymus-independent and thymus-derived lymphoid cells. II. Ultrastructural studies. J Exp Med (1972) 1.43
Incorporating patient preferences into randomized trials. J Clin Epidemiol (2000) 1.42
A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials (1999) 1.42
Great vessel, cardiac chamber, and wall growth patterns in normal children. Circulation (1975) 1.41
Whole-exome sequencing and an iPSC-derived cardiomyocyte model provides a powerful platform for gene discovery in left ventricular hypertrophy. Front Genet (2012) 1.40
Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta (2000) 1.40
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res (2000) 1.39
Multivariate analysis of glycosylated haemoglobin in insulin-treated diabetics. J R Soc Med (1985) 1.39
Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol (2001) 1.37
Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science (1981) 1.37
Changes in hospital antibiotic therapy after a quality-of-use study. Lancet (1977) 1.33
Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev (2001) 1.33
Part time work: one year's job share in Bristol. Br Med J (Clin Res Ed) (1984) 1.33
The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol (1998) 1.31
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis (2003) 1.30
Synergies and coincidence requirements between NO, cGMP, and Ca2+ in the induction of cerebellar long-term depression. Neuron (1997) 1.29
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol (2000) 1.28
Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer (2001) 1.28
Localization of O-GlcNAc modification on the serum response transcription factor. J Biol Chem (1992) 1.27
Surveillance of work-related asthma in selected U.S. states using surveillance guidelines for state health departments--California, Massachusetts, Michigan, and New Jersey, 1993-1995. MMWR CDC Surveill Summ (1999) 1.27
Microcinematographic and electron microscopic analysis of target cell lysis induced by cytotoxic T lymphocytes. Immunology (1979) 1.27
Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood (2000) 1.26
Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta (2001) 1.24
Pharmacologic and biochemical considerations of dimethyl sulfoxide. Ann N Y Acad Sci (1975) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology (1988) 1.22
Porcine haemophili and actinobacilli: characterization by means of API test strips and possible taxonomic implications. Can J Microbiol (1984) 1.21
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm (2001) 1.21
[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci (1991) 1.20
Strong coherence between solar variability and the monsoon in Oman between 9 and 6 kyr ago. Nature (2001) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol (1998) 1.19
Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. J Biol Chem (1995) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev (1996) 1.18